.png)
.png)
A GP has ten minutes with a woman who is eleven weeks pregnant and needs to remain on treatment for a long-term condition. The product information advises that the medicine be used only if the benefit clearly outweighs the risk. Beyond that sentence there is very little for either of them to rely on. Consultations of this kind occur daily in general practice and hospital clinics, and they seldom feature in national debate because the uncertainty falls on one clinician and one patient at a time. This week the Medicines and Healthcare products Regulatory Agency published a Women's Health Programme for 2026 to 2030, unveiled at the inaugural DIA-MHRA Global Summit during London Life Sciences Week, that aims to address the origin of that uncertainty much further upstream.
The numbers explain why. The agency reviewed 4,616 clinical trial applications submitted between 2019 and 2023. Pregnant women were included in 1.1 per cent of them and breastfeeding women in 0.6 per cent, while women make up 51 per cent of the population. The women's health minister, Baroness Merron, has called that position unacceptable. The figures describe what sponsors proposed, which is the stage at which a regulator has most influence, and they point to a deficit built into study design long before any patient is recruited.
The relevance to the NHS is structural. The health service seldom sponsors the pivotal trials that decide what a licence says, yet it absorbs the consequences of what they leave out. Clinicians prescribe under uncertainty, women are advised to stop treatment they may need or to continue without evidence on their side, and harms emerge after licensing, when they are costliest to the patient and hardest for the system to repair. The review led by Baroness Cumberlege into medicines and devices that caused avoidable harm criticised industry and regulators alike, and its findings remain a reference point for patients and campaigners. A regulator seen to act before harm occurs has a stake in rebuilding trust, and so does a health service that depends on it for every prescription.
The programme's reach has limits that its launch material does not dwell on. As far as published guidance indicates, UK law places no general duty on sponsors to include women in trials or to report results by sex, whereas the EU's clinical trials regulation requires the age and sex of participants to be justified. A regulator without that statutory lever relies on scientific advice, scrutiny of applications and persuasion. Sponsors have reasons to resist. Trials involving pregnancy are costlier, ethically more complex and slower to recruit, and the commercial penalty for excluding women arrives years later and falls on someone else. The measure of the programme will be whether its guidance turns encouragement into expectation, for instance by asking sponsors to justify exclusions in writing at the point of application. The published foreword does not settle that question. The detailed guidance will.
The commercial case is made prominently. The UK FemTech sector has annual turnover of nearly £300 million and has attracted £544 million of investment, and the agency estimates that closing the women's health gap could add at least £36 billion a year to the economy by 2040. That last figure is a projection and deserves the caution that applies to all such projections. The more tangible offer is earlier engagement with developers, so that sex-specific evidence is planned into development from the outset. For a small company, regulatory uncertainty is among the largest costs it carries, and early dialogue has real value. A cleared product still has to find a buyer, however, in a health service under tight financial control and with fragmented procurement. The renewed Women's Health Strategy for England, published in April, promised a challenge fund for women's health technology start-ups within two years. Regulatory clarity and a route into NHS adoption need to arrive together, or the evidence will accumulate with companies that cannot afford to sell it.
The summit setting also exposes a tension. The agency is under pressure to speed approvals and attract investment, and the programme promises faster innovation without compromising safety. Sex-specific evidence adds work at the front of development. It will save time overall only if it prevents later delay, such as post-licensing safety reviews, and that is a claim the agency will need to demonstrate with cases.
Data is where the NHS carries direct responsibility. The renewed strategy commits to rolling out patient-reported outcome and experience data in core women's health pathways. If that data is recorded consistently and linked to prescribing, it gives the regulator a means of seeing how medicines perform in the pregnant and breastfeeding women whom trials overlook. If recording remains patchy, post-marketing surveillance will continue to depend largely on voluntary Yellow Card reports. Trust leaders and research delivery networks control something nearer to hand. A sponsor willing to design a trial for pregnant participants needs sites with the obstetric and pharmacy infrastructure to run it, and a research office able to open the study quickly. Where that capacity is thin, the ambition will not convert into recruitment.
The timetable deserves more attention than it has received. Many medicines that reach patients in the early 2030s will have their pivotal trials designed over the next few years, and the eligibility criteria in those protocols are being settled now, in sponsors' offices and ethics submissions, long before any evidence appears. NHS leaders, regulators and industry all have a say in those decisions, and the period in which that say carries most weight is shorter than a strategy running to 2030 suggests. The programme can be judged by a simple test. When the GP in that consultation looks for an answer, there should be one to find.